BIOMÉRIEUX LEADS EUROPEAN EFFORT TO QUANTIFY DIAGNOSTICS’ VALUE TO COMBAT AMR
Through its co-leadership on the Value Dx Project, bioMérieux is accelerating pan-European efforts to quantify the medical, economic, and public health value of diagnostics for combating AMR.
Antibiotics are often overused and unnecessarily prescribed in community clinical settings. The goal is to demonstrate and assess—in the specific case of community-acquired acute respiratory tract infections—the value of diagnostics as a fundamental tool to optimize antibiotic treatments. The project seeks to facilitate and accelerate rigorous assessment and implementation of diagnostic technologies in healthcare settings by establishing the needed infrastructure, methods, processes, and approaches. It also aims to evaluate and solve major hurdles to adopting diagnostics for acute respiratory tract infections in community settings, including clinical education, psychosocial barriers, organizational challenges, and regulatory and reimbursement issues.
Value DX is coordinated by bioMérieux, the University of Antwerp, and the Wellcome Trust, with a EUR14M budget over 4 years. Funding is provided by the IMI 2 Joint Undertaking, supported by the EU’s Horizon 2020 research and innovation program, the European Federation of Pharmaceutical Industries and Associations (EFPIA), bioMérieux, Janssen Pharmaceutica N.V., Accelerate Diagnostics S.L., Abbott Laboratories, Bio-Rad Laboratories, Becton Dickinson (BD), and the Wellcome Trust.